References
- Larsson P, Wijkström H, Thorstenson A, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003;37(3):195–201.
- Liedberg F, Hagberg O, Holmäng S, et al. Local recurrence and progression of non-muscleinvasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015;49(4):290–295.
- Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995;172:33–36.
- Malmström PU, Thörn M, Lindblad P, et al. Increasing survival of patients with urinary bladder cancer. A nationwide study in Sweden 1960–1986. Eur J Cancer. 1993;29(13):1868–1872. A:
- Holmäng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165(4):1124–1128.
- Hentschel AE, van Rhijn BWG, et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urol Oncol. 2020;38(5):440-448.
- Linton KD, Rosario DJ, Thomas F, et al. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 2013;189(3):828–833.
- Kobayashi H, Kikuchi E, Mikami S, et al. Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression. BMC Urol. 2014;14(1):5.
- Wang EY, Larsson U, Gårdmark T, et al. What is the outcome after initial or delayed cystectomy for high-risk non-muscle invasive bladder cancer? A Swedish Nationwide analysis. Proceedings of the 32nd NUF Congress 2000 Reykjavik, Iceland, 5–8 June 2019.
- Malmström PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155:1903–1906.
- Kassouf W, Traboulsi SL, Schmitz-Dräger B, et al. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. Urol Oncol. 2016;34(10):460–468.
- Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–262.
- Koo K, Zubkoff L, Sirovich BE, et al. The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making. Urology. 2017;108:122–128.
- Lajer H, Jensen MB, Kilsmark J, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer. 2010;20(8):1307–1320.